
Nilanjan Ghosh, MD, reviews phase 3 data showing that tafasitamab plus lenalidomide and R-CHOP improved progression-free survival vs R-CHOP alone in patients with newly diagnosed high-risk DLBCL.

Nilanjan Ghosh, MD, reviews phase 3 data showing that tafasitamab plus lenalidomide and R-CHOP improved progression-free survival vs R-CHOP alone in patients with newly diagnosed high-risk DLBCL.

Peter Voorhees, MD, presents phase 3 MonumenTAL-3 data supporting talquetamab plus daratumumab, with or without pomalidomide, as a potential new standard for early relapsed/refractory multiple myeloma.

This presentation presents the first global clinical trial results evaluating the investigational bispecific antibody pumitamig combined with chemotherapy as a first-line treatment for advanced non-small cell lung cancer.

Phase II data show Silevertinib boosts responses and brain control in treatment‑naive EGFR non‑classical NSCLC, with manageable rash/diarrhea.

This presentation details results from the global Phase 3 FIGHT-302 trial, which evaluated pemigatinib compared to standard chemotherapy for patients with advanced or metastatic cholangiocarcinoma containing specific genetic rearrangements.

This phase 1b analysis from the ELEVATE study evaluated the combination of elacestrant and capivasertib in patients with ER-positive, HER2-negative advanced breast cancer whose tumors harbored alterations in the PI3K/AKT pathway. The combination demonstrated a manageable safety profile with no new safety concerns and showed encouraging antitumor activity, including durable disease control across a heavily pretreated population. These findings support further investigation of this all-oral regimen as a strategy to simultaneously target endocrine resistance and PI3K/AKT pathway–driven disease.

David M. Waterhouse, MD, MPH, reviews real-world claims data suggesting substantial underdiagnosis of Lambert-Eaton myasthenic syndrome among patients with small cell lung cancer and the need for improved recognition in oncology practice.

Jae Park, MD, discusses findings from the FELIX study showing that obecabtagene autoleucel demonstrated clinically meaningful activity and a manageable safety profile in adults with relapsed/refractory B-cell acute lymphoblastic leukemia, including those with extramedullary disease at lymphodepletion.

Timothy Cloughesy, MD, presents updated INDIGO data showing that vorasidenib provides durable progression-free survival benefit and delays subsequent intervention in patients with IDH-mutant grade 2 glioma.

This presentation details results from the phase 3 SUCCESSOR-2 clinical trial evaluating the combination of oral mezigdomide, carfilzomib, and dexamethasone against carfilzomib and dexamethasone alone. The study focused on patients with relapsed or refractory multiple myeloma who had previously been exposed to specific standard therapies. Findings indicate that adding mezigdomide significantly improves progression-free survival across all prespecified patient subgroups while presenting a predictable and manageable safety profile.

Barbara Burtness, MD, presents OrigAMI-4 cohort 1 data showing that subcutaneous amivantamab produced deep and durable antitumor activity with a manageable safety profile in previously treated recurrent or metastatic head and neck squamous cell carcinoma.

Rapid readout: sevabertinib delivers high, durable responses in HER2‑mutant advanced NSCLC, with manageable diarrhea and strong frontline benefit signals.

Mark Socinski, MD, highlights Stage 1 PRESERVE-003 data showing chemotherapy-free gotistobart improved survival and durable responses vs docetaxel in previously treated metastatic squamous NSCLC.

The HARMONi-6 study evaluated ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non–small cell lung cancer. The combination with ivonescimab demonstrated a meaningful overall survival advantage across key patient subgroups while maintaining a manageable and generally comparable safety profile. These findings support ivonescimab plus chemotherapy as a promising new frontline treatment option for this patient population

Marlana Orloff, MD, reviews primary OptimUM-02 data showing darovasertib plus crizotinib significantly improved progression-free survival and response rates versus investigator’s choice in first-line HLA-A2–negative metastatic uveal melanoma, with overall survival data not yet mature.

Rapid readout: Real-world lifileucel TIL shows 44% responses in metastatic melanoma, favoring early referral and manageable IL-2 toxicity.

Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.

Alison Schram, MD, discusses interim PYNNACLE phase 2 data showing that single-agent rezatapopt produced clinically meaningful responses and a manageable safety profile in heavily pretreated patients with TP53 Y220C–mutated advanced ovarian cancer.

This analysis from the SOHO-01 study evaluated the safety profile of sevabertinib in HER2-mutated non–small cell lung cancer, with a specific focus on treatment-related diarrhea. Diarrhea was frequently observed but generally low grade, short in duration, and manageable with standard supportive care and dose modifications. Findings also suggest that prior therapies and drug exposure levels may influence the risk of more severe diarrhea, providing useful context for clinical management.

Long-term data show avapritinib cuts systemic mastocytosis burden, delivers lasting responses, manageable safety, and boosts bone health markers.

Obrixtamig in combination with platinum-based chemotherapy demonstrated encouraging clinical activity in patients with DLL3-positive neuroendocrine carcinomas, with high response rates and durable disease control. The regimen showed a manageable safety profile, with adverse events consistent with its mechanism and no unexpected toxicities. These findings support further development of this combination as a potential first-line treatment option.

Support provided by Revolution Medicines. Content independently published by OncLive. This presentation describes a study evaluating daraxonrasib as an initial treatment for metastatic pancreatic cancer driven by RAS mutations. The therapy showed promising tumor response and disease control with a manageable safety profile, suggesting potential improvement over existing chemotherapy options. These findings support further investigation in larger clinical trials.

Taletrectinib is a next-generation targeted therapy for ROS1-positive non-small cell lung cancer that has shown strong and durable tumor responses in both treatment-naïve and previously treated patients. It demonstrates meaningful activity in the brain and maintains a manageable safety profile with mostly mild side effects. Overall, the findings support its use as an effective and well-tolerated treatment option in this patient population.

In this ASH 2025 presentation, Andrew A. Lane, MD, reports phase 2 data demonstrating that the tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet is feasible, yields high composite complete response rates, and facilitates allogeneic transplant in patients with newly diagnosed or relapsed/refractory BPDCN.

This presentation evaluates the long-term safety and effectiveness of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer, highlighting durable responses and manageable side effects, particularly in patients with KRAS mutations.

This presentation examines the effectiveness and clinical role of reusing chemotherapy after disease progression in patients with EGFR-mutated advanced non-small cell lung cancer.

Combination therapy with osimertinib and chemotherapy demonstrated substantially improved disease control and response durability compared with osimertinib alone. The benefit was consistent across key subgroups, including patients with brain metastases and different EGFR mutation types. While toxicity was higher with combination therapy, no new safety concerns were identified, supporting its potential role as a preferred first-line option in this high-risk population

This presentation explores patient-reported experiences during treatment for chronic lymphocytic leukemia using remote monitoring tools. It compares symptom patterns between different therapies and highlights how real-world data can support better symptom management and care decisions. Overall, the findings suggest differences in patient experiences that may help guide treatment choices and improve quality of life.

Ticiana Leal, MD, discusses frontline zongertinib in HER2-mutant non-small cell lung cancer, including activity in patients with active brain metastases, based on data from the BeamionLUNG-1 study presented at ELCC 2026.

UCSF real-world CLL study pits zanubrutinib vs acalabrutinib, showing fewer next treatments and AI-extracted adverse events.